Collection efficiency, calculations — and a reminder of your impact

Welcome to the second edition of Access Point, a newsletter for those who regularly work with the Spectra Optia^® Apheresis System from Terumo Blood and Cell Technologies. Read on for performance insights, helpful calculations, and more. And remember: What you do is valued and important. Just one proof point: A study found that 7 in 10 patients receiving long-term red blood cell exchange (RBCX) treatment had 40% fewer emergency visits.¹ Now that’s impact.

Therapeutics

FCR in RBCX = math that matters

Taking time to better understand the fraction of cells remaining (FCR) calculation and how it is used in an RBCX procedure is worthwhile. FCR is the percentage of the original red blood cell (RBC) volume remaining in the patient’s body at the end of an RBCX procedure. In sickle cell disease (SCD) patients, the number of original, or sickled, cells can be measured by the percentage of hemoglobin S (HbS%).

Some practitioners mistakenly believe the FCR percentage (FCR%) and HbS% are the same thing.

Keep reading →

Cell Collections

Spotlight on performance measurement: Collection efficiency

Collection performance measurements are an important consideration for apheresis collection sites. They can help you evaluate instrument performance and develop optimization techniques.

Two common calculations used to measure collection performance on Spectra Optia are collection efficiency 1 (CE1) and collection efficiency 2 (CE2).

Let’s take a closer look →

Your Questions, Answered

Dear Access Point,

Can HbS% be considered the same as FCR%?

— Brian in Pensacola, Florida

Dear Brian,

This is a question we get often. FCR% can be considered the same only if the patient’s HbS% is 100%. See the article above for a more detailed explanation.

If you have a specific question about the Spectra Optia system, let us know. We’ll feature a reader question in each Access Point edition. Be sure to tell us your first name, hometown, and state or province. Questions not featured will be answered directly via email.

Submit a Question

Resource Spotlight

RBCX Calculation Tool for Spectra Optia

Find instructions and tips in this guide.

Best-Practice Spotlight — Johns Hopkins Hospital

Think Peripheral Access First — Increasing Peripheral Access to Reduce Risk and Treatment Delays

Did You Know?

Overall collection efficiency for the mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols on Spectra Optia is greater than 50%.^2,3

U.S. clinical trials for the protocols were conducted on healthy, mobilized donors. For the MNC protocol, the CE2 calculation for CD34+ cells had a median of 74% (range 38%-111%).² For the CMNC protocol, the CE2 calculation for CD34+ cells averaged 62.4% ± 11.61.³ Remember, collection efficiency can be affected by many factors.

Events

Are you interested in hosting or attending a future Successions workshop?

Contact your local Terumo Blood and Cell Technologies representative or send us an email.

Coming soon: Live From Lakewood

Learn more about our live and interactive sessions from our headquarters in Lakewood, Colorado.

Schedule online: You can now request and schedule preventive maintenance for your Terumo Blood and Cell Technologies devices here.

Need Support?

You’re on the front lines of care, and we’re here to assist.

Contact us online or via 877.339.4228.

Sources

1. Tsitsikas DA, Sirigireddy B, Nzouakou R, et al. Safety, tolerability, and outcomes of regular automated red cell exchange transfusion in the management of sickle cell disease. J Clin Apher. 2016;31(6):545-550.

2. Terumo Blood and Cell Technologies. Comparing MNC collection using the COBE Spectra Apheresis System MNC protocol and the Spectra Optia system CMNC protocol in a clinical study. 2015. Part number TS-OPTI-00822.

3. Terumo Blood and Cell Technologies. Spectra Optia Apheresis System healthy donor study. 2012. Part number TS-OPTI-01619.